124 related articles for article (PubMed ID: 36304088)
1. A new scoring system to evaluate adjuvant chemotherapy for patients with T2N0M0 gastric cancer after D2 gastrectomy.
Xu Q; Kang WZ; Xiong JP; Shao XX; Li WK; Hu HT; Tian YT
World J Gastroenterol; 2022 Oct; 28(38):5626-5635. PubMed ID: 36304088
[TBL] [Abstract][Full Text] [Related]
2. [Safety and efficacy of adjuvant chemotherapy with oxaliplatin and S-1 for patients with locally advanced gastric cancer after D2 lymph nodes dissection].
Bao YD; Zhang H; Dong L; Jiang KW; Ye YJ; Wang S; Zhou J
Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Feb; 24(2):145-152. PubMed ID: 33508920
[No Abstract] [Full Text] [Related]
3. [A multi-center retrospective study of perioperative chemotherapy for gastric cancer based on real-world data].
Ding XW; Zheng ZC; Zhao Q; Zhai G; Liang H; Wu X; Zhu ZG; Wang HJ; He QS; He XL; Du YA; Chen LC; Hua YW; Huang CM; Xue YW; Zhou Y; Zhou YB; Wu D; Fang XD; Dai YG; Zhang HW; Cao JQ; Li LP; Chai J; Tao KX; Li GL; Jie ZG; Ge J; Xu ZF; Zhang WB; Li QY; Zhao P; Ma ZQ; Yan ZL; Zheng GL; Yan Y; Tang XL; Zhou X
Zhonghua Wei Chang Wai Ke Za Zhi; 2021 May; 24(5):403-412. PubMed ID: 34000769
[No Abstract] [Full Text] [Related]
4. Predictive test for chemotherapy response in resectable gastric cancer: a multi-cohort, retrospective analysis.
Cheong JH; Yang HK; Kim H; Kim WH; Kim YW; Kook MC; Park YK; Kim HH; Lee HS; Lee KH; Gu MJ; Kim HY; Lee J; Choi SH; Hong S; Kim JW; Choi YY; Hyung WJ; Jang E; Kim H; Huh YM; Noh SH
Lancet Oncol; 2018 May; 19(5):629-638. PubMed ID: 29567071
[TBL] [Abstract][Full Text] [Related]
5. Adjuvant chemotherapy for elderly patients (aged 70 or older) with gastric cancer after a gastrectomy with D2 dissection: A single center experience in Korea.
Jo JC; Baek JH; Koh SJ; Kim H; Min YJ; Lee BU; Kim BG; Jeong ID; Cho HR; Kim GY
Asia Pac J Clin Oncol; 2015 Dec; 11(4):282-7. PubMed ID: 25856172
[TBL] [Abstract][Full Text] [Related]
6. A clinical prognostic scoring system for resectable gastric cancer to predict survival and benefit from paclitaxel- or oxaliplatin-based adjuvant chemotherapy.
Qian J; Qian Y; Wang J; Gu B; Pei D; He S; Zhu F; Røe OD; Xu J; Liu L; Gu Y; Guo R; Yin Y; Shu Y; Chen X
Drug Des Devel Ther; 2016; 10():241-58. PubMed ID: 26966350
[TBL] [Abstract][Full Text] [Related]
7. Adjuvant chemotherapy, p53, carcinoembryonic antigen expression and prognosis after D2 gastrectomy for gastric adenocarcinoma.
He MM; Zhang DS; Wang F; Wang ZQ; Luo HY; Ren C; Jin Y; Chen DL; Xu RH
World J Gastroenterol; 2014 Jan; 20(1):264-73. PubMed ID: 24415881
[TBL] [Abstract][Full Text] [Related]
8. [Prognostic value of the tumor deposit in N0 gastric cancer by propensity score matching analysis].
Zhi C; Yang W; Li N; Zhang Z; Hua Y; Liu H
Zhonghua Wei Chang Wai Ke Za Zhi; 2019 Feb; 22(2):172-179. PubMed ID: 30799540
[TBL] [Abstract][Full Text] [Related]
9. Surgical care quality and oncologic outcome after D2 gastrectomy for gastric cancer.
Mrena J; Mattila A; Böhm J; Jantunen I; Kellokumpu I
World J Gastroenterol; 2015 Dec; 21(47):13294-301. PubMed ID: 26715812
[TBL] [Abstract][Full Text] [Related]
10. Adjuvant chemotherapy for elderly patients with gastric cancer after D2 gastrectomy.
Jin Y; Qiu MZ; Wang DS; Zhang DS; Ren C; Bai L; Luo HY; Wang ZQ; Wang FH; Li YH; Xu RH
PLoS One; 2013; 8(1):e53149. PubMed ID: 23359796
[TBL] [Abstract][Full Text] [Related]
11. Survival outcomes of adjuvant taxanes, platinum plus fluoropyrimidines versus platinum and fluoropyrimidines for gastric cancer patients after D2 gastrectomy: a retrospective propensity score-matched analysis.
Wu L; Feng Y; Wu Z; Xu H; Zhang C; Ning J; Wang R; Chen J; Xie M; Zhang Y; Bu L; Hao J; Ma T
World J Surg Oncol; 2021 Sep; 19(1):272. PubMed ID: 34507562
[TBL] [Abstract][Full Text] [Related]
12. The role of oxaliplatin in the adjuvant setting of different Lauren's type of gastric adenocarcinoma after D2 gastrectomy: a real-world study.
Cheng X; Yu S; Wang Y; Cui Y; Li W; Yu Y; Tang C; Jiang H; Ji Y; Sun Y; Wang X; Shen Z; Liu F; Liu TS
Gastric Cancer; 2019 May; 22(3):587-597. PubMed ID: 30426294
[TBL] [Abstract][Full Text] [Related]
13. Adjuvant capecitabine plus oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): 5-year follow-up of an open-label, randomised phase 3 trial.
Noh SH; Park SR; Yang HK; Chung HC; Chung IJ; Kim SW; Kim HH; Choi JH; Kim HK; Yu W; Lee JI; Shin DB; Ji J; Chen JS; Lim Y; Ha S; Bang YJ;
Lancet Oncol; 2014 Nov; 15(12):1389-96. PubMed ID: 25439693
[TBL] [Abstract][Full Text] [Related]
14. Adjuvant chemotherapy provided survival benefit for stage T2N0 gastric cancer with high-risk factors.
Wang Z; Yan J; Hu W; Zhang J; Huo B
Neoplasma; 2018; 65(4):592-598. PubMed ID: 29940758
[TBL] [Abstract][Full Text] [Related]
15. [Clinical value of superior mesenteric vein (No.14v) lymph node dissection in D2 gastrectomy for locally advanced distal gastric cancer].
Lu W; Zeng X; Li N; Liu H
Zhonghua Wei Chang Wai Ke Za Zhi; 2018 Oct; 21(10):1136-1141. PubMed ID: 30370512
[TBL] [Abstract][Full Text] [Related]
16. Favorable long-term outcomes of one-year adjuvant S-1 monotherapy for pathological stage II or III gastric cancer treated at a high-volume center.
Kano Y; Ohashi M; Hiki N; Takahari D; Chin K; Yamaguchi K; Tsuda Y; Shoji Y; Yasufuku I; Eto K; Ida S; Kumagai K; Nunobe S; Sano T
Gastric Cancer; 2018 Nov; 21(6):1024-1030. PubMed ID: 29700635
[TBL] [Abstract][Full Text] [Related]
17. Prognostic significance of the concomitant existence of lymphovascular and perineural invasion in locally advanced gastric cancer patients who underwent curative gastrectomy and adjuvant chemotherapy.
Hwang JE; Hong JY; Kim JE; Shim HJ; Bae WK; Hwang EC; Jeong O; Park YK; Lee KH; Lee JH; Cho SH; Chung IJ
Jpn J Clin Oncol; 2015 Jun; 45(6):541-6. PubMed ID: 25759484
[TBL] [Abstract][Full Text] [Related]
18. Adjuvant albumin-bound paclitaxel combined with S-1 vs. oxaliplatin combined with capecitabine after D2 gastrectomy in patients with stage III gastric adenocarcinoma: a phase III multicenter, open-label, randomized controlled clinical trial protocol.
Cheng X; Wu D; Xu N; Chen L; Yan Z; Chen P; Zhou L; Yu J; Cui J; Li W; Wang C; Feng W; Wei Y; Yu P; Du Y; Ying J; Xu Z; Yang L; Zhang Y
BMC Cancer; 2021 Jan; 21(1):56. PubMed ID: 33435909
[TBL] [Abstract][Full Text] [Related]
19. Prolonged adjuvant capecitabine chemotherapy improved survival of stage IIIA gastric cancer after D2 gastrectomy.
Feng WM; Tang CW; Guo HH; Bao Y; Fei MY
Biomed Pharmacother; 2015 May; 72():140-3. PubMed ID: 26054688
[TBL] [Abstract][Full Text] [Related]
20. [Clinical features and prognosis analysis of 21 gastric cancer patients with pathological complete response after neoadjuvant chemotherapy].
Peng L; Yang W; Zhang Z; Liu H; Hua Y
Zhonghua Wei Chang Wai Ke Za Zhi; 2017 Oct; 20(10):1168-1173. PubMed ID: 29130233
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
